Specialty Pharmacy

Top news of the day from across the health care landscape.

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia.

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study.

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

Top news of the day from across the health care landscape.

Risdiplam showed continued improvements in motor milestones and functions for patients with spinal muscular atrophy.

In 2016, an estimated 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women, according a CDC report.

On August 30, 2018, the FDA approved Merck’s doravirine (Pifeltro) a non-nucleoside reverse transcriptase inhibitor and doravirine/lamivudine/tenofovir (Delstrigo) a once-daily single tablet regimen for the treatment of HIV-1 infection in appropriate patients.

Procedure uses small incisions and a miniature video camera to reduce the risk of complications from surgery for lung cancer.

The FDA approved a Prior Approval Supplement for immune globulin intravenous (human), 10% liquid (Bivigam, ADMA Biologics) for patients with primary humoral immunodeficiency disease.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

From 2018 to 2040, the number of patients who will need chemotherapy each year is estimated to rise from 9.8 million to 15 million.

Promacta (eltrombopag, Novartis) 12.5 mg for oral suspension was distributed nationwide through specialty pharmacies.

New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.

Top news of the day from across the health care landscape.

Ramucirumab (Cyramza, Eli Lilly) is approved as a single agent in patients with elevated alpha fetoprotein who have been previously treated with sorafenib.

The pathway is intended to help patients by making more treatment options available through biosimilar and interchangeable products.

This product is a generic version of Genentech's Tarceva.

Compared with interferon beta-1a, ozanimod reduced less cortical grey matter volume in patients with relapsing forms of multiple sclerosis.

An investigational therapy for amyotrophic lateral sclerosis has shown promise in slowing the progression of the disease in patients with a genetic form of the disease.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Study finds the number of patients who are eligible for and may respond to checkpoint inhibitor therapies is higher than for genome-driven therapies.

Eighty-three percent of physicians excising more-than-necessary amounts of tissue on a regular basis during Mohs micrographic surgery.

Top news of the day from across the health care landscape.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discusses some of the ways that Walgreens is advancing care for patients with cancer.

Premier Inc. announced on Tuesday it is selling its specialty pharmacy business to ProCare Pharmacy LLC, a subsidiary of CVS Health Corporation.